Paper29100705
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.
Yan J and 10 others. Vaccine, 2018. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Papers, record 29100705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29100705
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cross Protection | Major topic |
| Hemagglutinin Glycoproteins, Influenza Virus | Major topic |
| Influenza Vaccines | Major topic |
| Orthomyxoviridae Infections | Major topic |
| Vaccines, DNA | Major topic |
| Animals | |
| Antibodies, Neutralizing | |
| Antibodies, Viral | |
| Consensus Sequence | |
| Electroporation | |
| Ferrets | |
| Guinea Pigs | |
| Hemagglutination Inhibition Tests | |
| Influenza A Virus, H1N1 Subtype | |
| Macaca mulatta | |
| Mice | |
| Mice, Inbred BALB C |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40883775 | Lipid nanoparticles-mRNA based on the consensus sequences of avian coronavirus S1 and N genes protect animals against multiple viral infections. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40883775 | PubMed |
| 40636108 | Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines. | Front Immunol | 2025 | https://conductscience.org/library/papers/40636108 | PubMed |
| 40398322 | DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo. | Vaccine | 2025 | https://conductscience.org/library/papers/40398322 | PubMed |
| 38193304 | DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models. | Hum Vaccin Immunother | 2024 | https://conductscience.org/library/papers/38193304 | PubMed |
| 36016306 | Progress towards the Development of a Universal Influenza Vaccine. | Viruses | 2022 | https://conductscience.org/library/papers/36016306 | PubMed |
| 35754779 | Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats. | Adv Nanobiomed Res | 2022 | https://conductscience.org/library/papers/35754779 | PubMed |
| 33920917 | The Intersection of Age and Influenza Severity: Utility of Ferrets for Dissecting the Age-Dependent Immune Responses and Relevance to Age-Specific Vaccine Development. | Viruses | 2021 | https://conductscience.org/library/papers/33920917 | PubMed |
| 33466810 | Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/33466810 | PubMed |
| 33430278 | The Next Generation of Influenza Vaccines: Towards a Universal Solution. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/33430278 | PubMed |
| 32784907 | Immunogenicity and Protective Efficacy of Influenza A DNA Vaccines Encoding Artificial Antigens Based on Conservative Hemagglutinin Stem Region and M2 Protein in Mice. | Vaccines (Basel) | 2020 | https://conductscience.org/library/papers/32784907 | PubMed |
| 32328416 | In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/32328416 | PubMed |
| 32059697 | Better influenza vaccines: an industry perspective. | J Biomed Sci | 2020 | https://conductscience.org/library/papers/32059697 | PubMed |
| 30262507 | A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/30262507 | PubMed |
| 30062926 | A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses. | Hum Gene Ther | 2018 | https://conductscience.org/library/papers/30062926 | PubMed |
| 30038621 | A Review of DNA Vaccines Against Influenza. | Front Immunol | 2018 | https://conductscience.org/library/papers/30038621 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29100705
GET https://conductscience.org/api/papers/v1/29100705/authors